MedPage Today: Is it safe to share Alzheimer's disease biomarker results with older adults who don't have cognitive impairment? In the short-term at least, the answer appears to be "yes," according to a study of Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4) clinical trial candidates. Older Adults who learned they had elevated amyloid levels didn't experience more short-term depression, anxiety, or suicidality than those who learned they didn't have elevated amyloid, reported Joshua Grill, PhD, of University of California, Irvine, and colleagues in JAMA Neurology. ... This may be the largest study to date about delivering Alzheimer's biomarker information to cognitively unimpaired…
Read More
Hand sanitizer has become an integral part of the COVID-19 health toolbox, especially when soap and water is not available. However, some brands of hand sanitizers pose a new threat to our health. Increased demand during the pandemic has caused shortages of well-known U.S. brands, and now many new companies are selling hand sanitizer products that contain methanol, commonly known as wood alcohol. The U.S. Food & Drug Administration (FDA) has recalled and imposed import bans on dozens of brands found to contain the toxic chemical. It also is working with major retailers to pull those products off shelves. Methanol…
Read More
UCI MIND, the Institute for Memory Impairments and Neurological Disorders at UCI, has been awarded a $14.4 million grant from the National Institute on Aging, one of the National Institutes of Health, to sustain critical research and education as Orange County’s only Alzheimer’s Disease Research Center. The NIA funds only 32 of these centers at major academic institutions across the U.S. They conduct groundbreaking research to improve the understanding, diagnosis, care and treatment for people with Alzheimer’s disease and related dementias. “The value of the Alzheimer’s Disease Research Center is immeasurable to both the campus and the community,” said Pramod…
Read More
Composed of thought leaders in the areas of Alzheimer’s disease, research, and brain health prevention, education, and risk reduction, HFC’s Science Advisory Board members come from a variety of prestigious institutions. These experts are at the forefront of groundbreaking research and clinical practice in the field. Inaugural members of the board include Dr. Megan Jones-Bell, Annie Fenn, M.D., Lisa Genova, Ph.D, Joshua Grill, Ph.D, Dr. Lisa Mosconi, Ph.D, Amanda Smith, M.D.,Dr, Wendy Suzuki, Richard S. Isaacson, M.D. Josh Grill, Associate Professor, Psychiatry & Human Behaviorphoto: steve zylius/UCI
Read More
The 31st Annual SoCal Alzheimer's Disease Research Conference is coming up! Learn how researchers are “Tackling Dementia with Technology” Register today: https://conference.mind.uci.edu
Read More
The UCI Blood Donor Center is now offering free COVID-19 antibody testing for qualified donors who donate blood or platelets. This is exclusively available at the donor center in Orange, not at mobile drives. Testing is open to all, not just UCI employees. Antibody testing does not diagnose a current case of COVID. It may help determine whether a person was previously infected, but not in all cases. Please read this Q & A to better understand the COVID antibody test. The blood donor center is located in Pavilion 3 next to Occupational Health. Hours are Mon., Tues., Thurs., Fri.…
Read More
The Alzheimer’s Impact Movement and Alzheimer’s Association need your advocacy support: The Promoting Alzheimer’s Awareness to Prevent Elder Abuse Act (H.R. 6813/S.3703) is critical legislation which would require the Department of Justice to develop training materials to assist professionals who support victims of abuse living with Alzheimer’s and other dementia in order to improve the quality of their interactions with this vulnerable population and help protect them from elder abuse. Support for this legislation has been growing, but to keep up the momentum, it is critical that your Senators hear from you today. Please ask your Senators to co-sponsor and pass…
Read More
Contributed by Hayk Davtyan, PhD Vaccines have become one of the most discussed topics during the COVID-19 pandemic. From development to distribution, the whole world has their eyes on a new vaccine. However, promising new data has now brought common vaccines even to the forefront of discussion in the study of Alzheimer’s disease (AD). At the 2020 Alzheimer’s Association International Conference this week (#AAIC20), newly presented data shows how flu and pneumonia vaccines may lower the risk for Alzheimer’s disease (AD). Hayk Davtyan, PhD Previous studies have shown the possible connection between vaccination and reducing cognitive decline. Yet, there has…
Read More
Dr. Ahmad Sajjadi UCI MIND faculty member, Ahmad Sajjadi, MD, PhD, was recently named a member of the Alzheimer’s Clinical Trials Consortium (ACTC) Early Career Project Evaluation Committee (PEC). The ACTC is a clinical trials network designed to accelerate and expand studies for therapies in Alzheimer’s disease and related dementias. UCI MIND has been a member of the ACTC network since its inception in 2018. The PEC of the ACTC is an important early first step in determining what trials the network will take on and in this initiative will provide mentorship for early career members. Dr. Sajjadi is an Assistant…
Read More
#AAIC20 kicks off today! A virtual week-long international conference covering the latest topics in #Alzheimers and #dementia science and healthcare. Today, Dr. Vivek Swarup from UCI MIND led a discussion on #genetics and omics of Alzheimer’s – his presentation available On Demand at AAIC: aaic2020.vfairs.com
Read More
